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COMMENTARY

E-cigarettes: effective cessation tools or
public health threat?
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In a short time, electronic cigarettes have become a multi-billion dollar industry. Since their introduction to the market,
prevalence of ever-use among smokers in the USA appears to
have increased from 2% in 2010 to >30% in 2012, and the rate
of increase appears to be similar in the United Kingdom, Ireland
and other Western countries according to a special
Eurobarometer survey in 2014.1 The e-cigarette market is estimated to be worth over $3 billion. However, there is no consensus on the role of e-cigarettes and their contribution to the
provision of smoking cessation (SC) services, nor to global tobacco control.
At the Conference of the Parties to the WHO Framework
Convention on Tobacco Control in September 2014, the secretariat presented a report outlining the current facts concerning ecigarettes, put forth an opinion on these devices, and offered
considerations on options for regulation.2 This was on the tail
of two contrasting letters to Margaret Chan, Director General of
the WHO, submitted by scientists from many disciplines including tobacco control, public health, epidemiology, pharmacology
and the clinical sciences (Letters to Dr Chan; June 2014). One letter stated that e-cigarettes offer huge prospective gains by
reducing the prevalence of cigarette smoking and subsequently,
the harm done by smoking. Those in favour of this position
therefore requested support for the introduction and widespread availability of e-cigarettes. The other letter cautioned restraint, citing the possible damage that e-cigarettes could have
on tobacco control.
For those favouring the widespread proliferation of ecigarettes, the main considerations appear to be the efficacy
and safety of e-cigarettes with regards to SC and potential for
harm reduction. For those cautioning restraint the main consideration seems to be the possible effects these products may
have on broad tobacco control measures such as smoking

prevalence among children and young people, the possibility of
relapse among ex-smokers, the impact on smokefree laws, the
effects on advertising and sponsorship and the feared influence
of the tobacco industry. Although both groups are, of course,
concerned about all these issues, the discourse suggests that
priorities may be somewhat different for different scientists.
So what does the evidence say? On the whole, it remains
inconclusive.
With regard to the potential efficacy of e-cigarettes as a
smoking cessation tool, two randomized controlled trial (RCT)
studies suggest that e-cigarettes may be helpful. One study
found that e-cigarettes containing nicotine are as effective as
nicotine patches for smoking cessation when used as directed.3
In this study [n ¼ 657], one group of participants received vouchers for nicotine patches by post and were encouraged to use
them, while the other groups were given e-cigarettes—one with
and one without nicotine. In another RCT [n ¼ 300], smokers
were randomized to three groups (patches, e-cigarettes with
nicotine, e-cigarettes without nicotine). This study found that at
2, 4 and 12 weeks, there was a statistically significant difference
between the two groups with e-cigarettes containing nicotine
and the group with non-nicotine containing devices. However,
there was no difference between the groups with regard to the
overall reduction in the number cigarettes smoked at 24 or 52
weeks.4 In addition to these, there are many other small-scale
trials, some of which show positive and some of which have
negative results which may be considered inconclusive. These
studies often address particular aspects of efficacy which are of
concern (e.g. efficacy in key sub-populations), but they do not
resolve the overall question of the efficacy of e-cigarettes for
cessation. An interesting ‘real world’ study which was part of
the continuing English Smoking Toolkit Study found that ecigarette users had a better quit rate than those who used ‘over
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the counter’ nicotine replacement products, or than those who
succeeded in quitting without any form of nicotine.5 The survey
reports high e-cigarette use among ex-smokers, which raises
questions regarding the role of e-cigarettes in maintaining abstinence or as a gateway to relapse.
The approach to establishing safety has included demands
for accurate information on e-cigarette contents and basic ingredients, which was initially very limited but is now increasing
thanks to labelling by makers and analysis by independent scientists. However, the wide range of available devices (some estimates exceed 500 variants) reduces confidence that the
contents are reliably known. For the purpose of this article, only
nicotine containing devices are relevant to this discussion.
Within these products, the main constituents are reported to be
nicotine, propylene glycol, glycerine and flavours which of
course when vaporized are released as particles of varying sizes
which have not been well characterized. Particle size may be a
consideration in itself, distinct from the actual composition of
the particles. All of these substances have toxicity and when
vaporized are inhaled into the lungs and released into the atmosphere. The relevance of animal studies showing potential
toxicity from e-cigarettes are uncertain but to date, they are
thought to be low.6 At least two human-based studies show
acute but mild toxicity on lung function: one demonstrates an
increase in airway resistance with active e-cigarette usage7 and
one indicates a decrease in FEV1/FVC ratio, but only in passive
exposure to e-cigarettes.8 It is too soon to be confident about
long-term toxicity. A knowledge of the constituents indicates
that the effects may not be severe, with one estimate suggesting that in comparative terms it may be as little as 5% that due
to cigarette smoking.9 However, this estimate is based on a
modelling study where the inputs for the effects of e-cigarettes
are reported to be largely unknown for these relatively new
devices.
The possible long-term effects on tobacco control are also
largely unknown. Prevalence studies referred to earlier suggest
that adolescences and young adults are using e-cigarettes in
increasing numbers.10 Most studies find that young people who
use e-cigarettes also use tobacco products, though there are instances where young people try e-cigarettes without having
tried tobacco.11 The possible gateway effect to cigarette smoking
is not resolved. Studies conducted in the UK have not shown a
link to date but research from the USA is starting to indicate
that e-cigarettes may serve as a gateway in some circumstances.12, 13
The effects that e-cigarette use may have on smokefree laws
are no less complex. Many purport that the vapour released
from e-cigarettes is harmless and therefore should not be
banned in indoor/public places. However, the possibility that
the vapour may be confused with smoke has led some authorities to ban ‘vaping’ where smoking is banned with the aim of
ensuring continued support for Article 8 of the WHO FCTC and
avoiding the confusion that e-cigarette use in public may affect
attitudes and implementation of smokefree laws. Countries
contemplating policies towards the tobacco ‘endgame’ (e.g.
Ireland, Finland, Scotland, New Zealand and Singapore) are also
grappling with the policy implications that e-cigarettes may
have on smokefree legislation.14
Perhaps the greatest challenge that e-cigarettes may pose
for tobacco control would be the actions and reactions of the tobacco industry. With the e-cigarette market, we see a revival of
the difficulties that marketing, advertising, sponsorship and
promotion of cigarettes posed for tobacco control and that were

subsequently reflected in WHO FCTC Article 13. Perhaps even
more concerning is the threat posed by the consequences of
ownership of a large and seemingly increasing proportion of the
e-cigarette industry by the tobacco industry, which directly
challenges implementation of WHO Article 5.3, requiring governments to refuse the tobacco industry access to policy formation in public health and is regarded among the most important
of tobacco control measures. It seems possible that the proposed provisions of the Transatlantic Trade and Investment
Partnership (TTIP) may also be used to threaten TC. In the
European Union, multinational corporations may try to use
TTIP to challenge the EU Tobacco Products Directive regulations
on e-cigarettes, further muddling the already unclear circumstances surrounding the right of Member States to legislate for
public health of their citizens.
Data to support or refute these growing hopes for, or concerns regarding, e-cigarettes are yet not available and will likely
not become available during this rapidly evolving situation.
History, however, suggests caution. Both in Europe and the
USA, efforts by scientists to collaborate with the tobacco industry in the 1950s, 1960s and 1970s to find safer nicotine delivery
devices had the net effect of only delaying the inevitable conclusion that the tobacco industry’s aims are incompatible with
public health.15, 16 Will history repeat itself with this new,
sophisticated, less toxic device or will public health learn the
lessons from history and reject the extravagant hopes placed in
a technology which, at its most benign can be seen as another
nicotine replacement therapy with unpredictable prospects of
success?
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